<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01145885</url>
  </required_header>
  <id_info>
    <org_study_id>1230.23</org_study_id>
    <secondary_id>2009-018199-32</secondary_id>
    <nct_id>NCT01145885</nct_id>
  </id_info>
  <brief_title>BI 6727 (Volasertib) Human ADME Trial in Various Solid Tumours</brief_title>
  <official_title>Investigation of the Metabolism, Excretion and Pharmacokinetics of an Openlabel Single Dose of 300 mg [14C]Volasertib Administered Intravenously in Patients With Various Solid Tumours With a Possible Extension Phase With Nonlabelled Drug</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Investigation of absorption, distribution, metabolism and excretion (ADME) and assessment of
      safety, tolerability and preliminary therapeutic effects of [14C]volasertib in patients with
      advanced solid tumours.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Individual time course profiles of 14C-radioactivity in nmol/L in whole blood, plasma and urine and in nmol/kg for faeces</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Individual time course profiles of BI 6727 and its metabolite CD 10899 in plasma and urine</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Estimation of pharmacokinetic parameters using non-compartmental methods: from plasma and urinary concentrations of BI 6727 and its metabolite CD 10899; from whole blood, plasma, urinary and faecal concentrations of the 14C-radioactivity</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate and extent of excretion mass balance based on the total radioactivity in urine and faeces</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time dependency (if feasible) of Cblood cells/Cplasma ratio and Cblood/Cplasma ratio of 14C-radioactivity</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Elucidation of metabolite structures and identification of major metabolites in plasma, urine, and faeces (if feasible) in comparison with various animal species (will be reported separately)</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events as a measure of safety</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability of BI 6727</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of preliminary therapeutic effects of BI 6727</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>BI 6727</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BI 6727 cycles in every 21 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 6727</intervention_name>
    <description>PLK-1 inhibitor</description>
    <arm_group_label>BI 6727</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Inclusion Criteria 1. Patients with histologically or cytologically confirmed
             diagnosis of advanced, non resectable and / or metastatic solid tumour

          -  Inclusion Criteria 2. Male

          -  Inclusion Criteria 3. Age &gt;=18 and =&lt;70 years

          -  Inclusion Criteria 4. Written informed consent

          -  Inclusion Criteria 5. Eastern Cooperative Oncology Group (ECOG) performance score =&lt;2

          -  Inclusion Criteria 6. Recovery from Common Terminology Criteria for Adverse Events
             (CTCAE) Grade &gt;=2 therapy-related toxicities from previous chemo-, hormone-, immuno-,
             or radiotherapy

        Exclusion criteria:

          -  Exclusion Criteria 1. Serious concomitant non-oncological disease considered by the
             investigator

          -  Exclusion Criteria 2. Active infectious disease

          -  Exclusion Criteria 3. Viral hepatitis, Human Immunodeficiency Virus (HIV) infection

          -  Exclusion Criteria 4. Clinical evidence of active brain metastasis during the past 6
             months

          -  Exclusion Criteria 5. Second malignancy currently requiring active therapy

          -  Exclusion Criteria 6. Absolute neutrophil count less than 1,500/mm3

          -  Exclusion Criteria 7. Platelet count less than 100,000/mm3

          -  Exclusion Criteria 8. Total bilirubin greater than 1.5 mg/dL

          -  Exclusion Criteria 9. Aspartate amino transferase (AST) and / or alanine amino
             transferase (ALT) greater than 2.5 times the upper limit of normal (if related to
             liver metastases greater than five times the upper limit of normal)

          -  Exclusion Criteria 10. Serum creatinine greater than 1.5x Upper Limit of Normal (ULN).

          -  Exclusion Criteria 11. Known history of QT/QTcF-prolongation

          -  Exclusion Criteria 12. Patients who are sexually active and having a partner with
             childbearing potential and unwilling to use a medically acceptable method of
             contraception

          -  Exclusion Criteria 13. Treatment with other investigational drugs or participation in
             another clinical trial

          -  Exclusion Criteria 14. Chemo-, radio- immuno-, or molecular-targeted cancer-therapy
             within the past four weeks prior to start of therapy or concomitantly with this trial.
             This restriction does not apply to steroids and bisphosphonates.

          -  Exclusion Criteria 15. Alcohol abuse

          -  Exclusion Criteria 16. Life expectancy less than 12 weeks

          -  Exclusion Criteria 17. Potent Cytochrome P450 enzyme (CYP) 3A4 and P-glycoprotein
             inhibitors or inducers

          -  Exclusion Criteria 18. History of allergy/hypersensitivity
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1230.23.36001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2010</study_first_submitted>
  <study_first_submitted_qc>June 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2010</study_first_posted>
  <last_update_submitted>October 31, 2013</last_update_submitted>
  <last_update_submitted_qc>October 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <pending_results>
    <submitted>October 23, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

